Although these regulatory actions are still at an early stage, they provide manufacturers with advance notice of substances that could become subject to new hazard classifications, allowing companies to assess potential impacts on product portfolios and compliance strategies.
Two substances enter the public consultation phase
The latest consultations concern proposals for the harmonised classification and labelling (CLH) of Dimethyl Imidazolidinone and Benzyl Benzoate.
During the consultation period, manufacturers, industry associations, researchers and other stakeholders may submit scientific data, toxicological evidence and technical comments for consideration. The information received will support the scientific evaluation carried out by ECHA’s Committee for Risk Assessment (RAC).
Following the RAC opinion, the European Commission will decide whether to incorporate the proposed classifications into Annex VI of the CLP Regulation, making them legally binding across the European Union.
Benzyl Benzoate deserves particular attention
Among the substances under review, Benzyl Benzoate is of particular relevance to cosmetic manufacturers.
The ingredient is widely used as both a fragrance component and a solvent and is already regulated under the EU Cosmetics Regulation as one of the recognised fragrance allergens, requiring label declaration above specified concentration thresholds.
Any future changes to its harmonised hazard classification could have wider regulatory implications, including updates to cosmetic safety assessments, Cosmetic Product Safety Reports (CPSRs), Product Information Files (PIFs) and other compliance documentation.
Although no regulatory changes have been adopted at this stage, companies using Benzyl Benzoate may wish to follow the scientific review closely.
Butyrolactone moves to the next regulatory stage
Alongside the new consultations, ECHA has published a Classification and Labelling (CLH) intention for Butyrolactone.
Unlike a formal CLH proposal, a classification intention does not trigger a public consultation. Instead, it indicates that a Member State intends to prepare a harmonised classification dossier for the substance.
For industry, this serves as an early indication that the substance may undergo a future hazard assessment, giving companies additional time to review formulations, regulatory documentation and potential business impacts before any formal proposal is submitted.
Why monitoring CLH developments matters
The publication of CLH proposals and classification intentions does not immediately change the legal status of a substance. However, these milestones provide valuable insight into potential future regulatory developments.
By monitoring ECHA’s classification activities at an early stage, manufacturers can identify ingredients that may require closer evaluation, prepare for possible updates to hazard communication and assess whether future regulatory changes could affect product formulations or compliance obligations.
Maintaining awareness of these developments allows businesses to respond proactively rather than waiting until new classifications become legally binding under the CLP Regulation.
